subscribeSubscribe
price-trendAsk Us
Enforcement Report - Week of February 22, 2023

Enforcement Report - Week of February 22, 2023
FDA
22 Feb 2023
Share Share
Enforcement Report - Week of January 4, 2023

Enforcement Report - Week of January 4, 2023
FDA
04 Jan 2023
Share Share
Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older

Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older
BUSINESSWIRE
02 Dec 2021
Share Share
Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more

Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more
BUSINESSWIRE
23 Nov 2021
Share Share
FDA`s ADAC unanimously backs Takeda`s drug for post-transplant cytomegalovirus

FDA`s ADAC unanimously backs Takeda`s drug for post-transplant cytomegalovirus
Z. Brennan ENDPTS
08 Oct 2021
Share Share
Hikma launches Ganciclovir for Injection, USP

Hikma launches Ganciclovir for Injection, USP
PRESS RELEASE
22 Jun 2021
Share Share
Phase 3 Trial Subgroup Analysis Across SOT Types Supports Efficacy of Maribavir

Phase 3 Trial Subgroup Analysis Across SOT Types Supports Efficacy of Maribavir
PRESS RELEASE
07 Jun 2021
Share Share
FDA Action Alert: EyePoint Pharma and Merck

FDA Action Alert: EyePoint Pharma and Merck
Mark Terry BIOSPACE
05 Nov 2018
Share Share